Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of CAPRELSA is substantial. |
Clinical Added Value
| minor |
The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
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
thAjXx1NnkM4r8su
